Antimicrobial Stewardship Program to Reduce Antiretroviral Medication Errors in Hospitalized Patients with Human Immunodeficiency Virus Infection

被引:19
作者
Sanders, Jamie [1 ]
Pallotta, Andrea [2 ]
Bauer, Seth [2 ]
Sekeres, Jennifer [2 ]
Davis, Ramona [2 ]
Taege, Alan [3 ]
Neuner, Elizabeth [2 ]
机构
[1] SoutheastHEALTH, Dept Pharm, Cape Girardeau, MO USA
[2] Cleveland Clin, Dept Pharm, Cleveland, OH 44195 USA
[3] Cleveland Clin, Dept Infect Dis, Cleveland, OH 44195 USA
关键词
INTERVENTIONS; THERAPY;
D O I
10.1086/675287
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective.Evaluate antimicrobial stewardship interventions targeted to reduce highly active antiretroviral therapy (HAART)-- or opportunistic infection (OI)--related medication errors and increase error resolution.Design.Retrospective before-after study.Setting.Academic medical center.Patients.Inpatients who were prescribed antiretroviral therapy before the intervention (January 1, 2011, to October 31, 2011) and after the intervention (July 1, 2012, to December 31, 2012). Patients treated with lamivudine or tenofovir monotherapy for hepatitis B were excluded.Methods.Antimicrobial stewardship interventions included education, modification of electronic medication records, collaboration with the infectious diseases (ID) department, and prospective audit and review of HAART and OI regimens by an ID clinical pharmacist.Results.Data for 162 admissions from the preintervention period and 110 admissions from the postintervention period were included. The number of admissions with a medication error was significantly reduced after the intervention (81 [50%] of 162 admissions vs 37 (34%) of 110 admissions; P < .00)1. A total of 124 errors occurred in the preintervention group (mean no. of errors, 1.5 per admission), and 43 errors occurred in the postintervention group (mean no. of errors, 1.2 per admission). The most common error types were major drug interactions and dosing in the preintervention group and renal adjustment and OI-related errors in the postintervention group. A significantly higher error resolution rate was observed in the postintervention group (36% vs 74%; P < .001). After adjustment for potential confounders with logistic regression, admission in the postintervention group was independently associated with fewer medication errors (odds ratio, 0.4 [95% confidence interval, 0.24--0.77]; P = .005). Overall, presence of an ID consultant demonstrated a higher error resolution rate (32% without a consultation vs 68% with a consultation; P = .002).Conclusions.Multifaceted, multidisciplinary stewardship efforts reduced the rate and increased the overall resolution of HAART-related medication errors.
引用
收藏
页码:272 / 277
页数:6
相关论文
共 50 条
  • [41] Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America
    Abraham, Alison G.
    Lau, Bryan
    Deeks, Steven
    Moore, Richard D.
    Zhang, Jinbing
    Eron, Joseph
    Harrigan, Richard
    Gill, M. John
    Kitahata, Mari
    Klein, Marina
    Napravnik, Sonia
    Rachlis, Anita
    Rodriguez, Benigno
    Rourke, Sean
    Benson, Constance
    Bosch, Ron
    Collier, Ann
    Gebo, Kelly
    Goedert, James
    Hogg, Robert
    Horberg, Michael
    Jacobson, Lisa
    Justice, Amy
    Kirk, Greg
    Martin, Jeff
    McKaig, Rosemary
    Silverberg, Michael
    Sterling, Timothy
    Thorne, Jennifer
    Willig, James
    Gange, Stephen J.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2011, 174 (06) : 727 - 735
  • [42] Histoplasmosis in Patients With Cell-Mediated Immunodeficiency: Human Immunodeficiency Virus Infection, Organ Transplantation, and Tumor Necrosis Factor-α Inhibition
    Luckett, Keith
    Dummer, J. Stephen
    Miller, Geraldine
    Hester, Sydney
    Thomas, Lora
    OPEN FORUM INFECTIOUS DISEASES, 2015, 2 (01):
  • [43] Changing Epidemiology of Hepatitis C Virus Genotype among Patients with Human Immunodeficiency Virus/Hepatitis C Virus Co-Infection in China
    Chen, Weilie
    Liao, Baolin
    Hu, Fengyu
    Nie, Jingmin
    Lan, Yun
    Li, Huiqin
    Lu, Ruichao
    Gao, Yanqing
    Song, Yuxia
    Zhao, Qingxia
    Zheng, Yuhuang
    Tang, Xiaoping
    Cai, Weiping
    PLOS ONE, 2016, 11 (09):
  • [44] Apples to Apples? A Comparison of Real-World Tolerability of Antiretrovirals in Patients with Human Immunodeficiency Virus Infection and Patients with Primary Biliary Cholangitis
    Turvey, Shannon L.
    Saxinger, Lynora
    Mason, Andrew L.
    VIRUSES-BASEL, 2022, 14 (03):
  • [45] Calcaneal Quantitative Ultrasonography and Urinary Retinol-Binding Protein in Antiretroviral-Treated Patients With Human Immunodeficiency Virus in Uganda: A Pilot Study
    Costa, Cecilia
    Scabini, Silvia
    Kaimal, Arvind
    Kasozi, William
    Cusato, Jessica
    Kafufu, Bosco
    Borderi, Marco
    Mwaka, Erisa
    Di Perri, Giovanni
    Lamorde, Mohammed
    Calcagno, Andrea
    Castelnuovo, Barbara
    JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (02) : 263 - 272
  • [46] Incidence and risk factors of hepatitis C virus infection among human immunodeficiency virus (HIV) patients in a large HIV clinic in South Korea
    Lee, Shinwon
    Lee, Sun Hee
    Lee, Su Jin
    Kim, Kye-Hyung
    Lee, Jeong Eun
    Cho, Heerim
    Lee, Seung Geun
    Chung, Joo Seop
    Kwak, Ihm Soo
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2016, 31 (04) : 772 - 778
  • [47] Using Administrative Claims Data to Estimate Virologic Failure Rates among Human Immunodeficiency Virus-Infected Patients with Antiretroviral Regimen Switches
    Broder, Michael S.
    Juday, Timothy
    Chang, Eunice Y.
    Jing, Yonghua
    Bentley, Tanya G. K.
    MEDICAL DECISION MAKING, 2012, 32 (01) : 118 - 131
  • [48] The burden of hepatitis B virus (HBV) infection, genotypes and drug resistance mutations in human immunodeficiency virus-positive patients in Northwest Ethiopia
    Deressa, Tekalign
    Damtie, Debasu
    Fonseca, Kevin
    Gao, Shan
    Abate, Ebba
    Alemu, Shitaye
    Aleka, Yetemwork
    Swain, Mark G.
    van Marie, Guido
    Coffin, Carla S.
    PLOS ONE, 2017, 12 (12):
  • [49] The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro
    Drogan, Daniel
    Rauch, Pia
    Hoffmann, Daniel
    Walter, Hauke
    Metzner, Karin J.
    ANTIVIRAL RESEARCH, 2010, 86 (03) : 312 - 315
  • [50] Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015
    Rossetti, B.
    Bai, F.
    Tavelli, A.
    Galli, M.
    Antinori, A.
    Castelli, F.
    Pellizzer, G.
    Cozzi-Lepri, A.
    Bonora, S.
    Monforte, A. d'Arminio
    Puoti, M.
    De Luca, A.
    CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 (04) : 422 - 427